MD-Onco Pub Date : 2022-06-02 DOI: 10.17650/2782-3202-2022-2-2-63-67

М. О. Rusanov, L. Kogoniya, V. Shikina

引用次数: 0

Nivolumab in treatment of relapsed Hodgkin lymphoma 纳武单抗治疗复发霍奇金淋巴瘤

MD-Onco Pub Date : 2022-06-02 DOI: 10.17650/2782-3202-2022-2-2-38-44

T. Valiev, A. Odzharova

引用次数: 0

Serous borderline ovarian tumor and pregnancy. Clinical case 浆液性交界性卵巢肿瘤与妊娠。临床病例

MD-Onco Pub Date : 2022-06-02 DOI: 10.17650/2782-3202-2022-2-2-24-28

M. Chekalova, L. N. Aminova, I. A. Karev, A. Kozub

引用次数: 0

Endoscopic techniques used in scarring stenoses after laryngectomy. Clinical observation 内镜技术在喉切除术后瘢痕性狭窄中的应用。临床观察

MD-Onco Pub Date : 2022-06-02 DOI: 10.17650/2782-3202-2022-2-2-45-50

I. N. Iurichev, V. Vereshchak, A. Mudunov, A. A. Marienko

引用次数: 0

Clinical and morphological observation of a 19-year-old patient with alveolar rhabdomyosarcoma of the head and neck region 1例19岁头颈部肺泡横纹肌肉瘤的临床及形态学观察

MD-Onco Pub Date : 2022-06-02 DOI: 10.17650/2782-3202-2022-2-2-14-23

Yu. E. Ryabukhina, A. Fedenko, P. A. Zeynalova, O. L. Timofeeva, F. М. Abbasbeyli, D. Chekini, A. Mudunov, A. Batsev, O. V. Sinitsyna, A. G. Zhukov, L. A. Shestakova, G. Allakhverdieva, I. Yurichev

引用次数: 0

Is total mesorectal excision necessary for treatment of upper rectal cancer? 治疗上直肠癌需要全肠系膜切除吗?

MD-Onco Pub Date : 2022-06-02 DOI: 10.17650/2782-3202-2022-2-2-29-37

J. Madyarov, A. Rasulov, A. E. Kulikov, Z. Rasulov, M. Fedyanin, A. Polynovskiy

{"title":"Is total mesorectal excision necessary for treatment of upper rectal cancer?","authors":"J. Madyarov, A. Rasulov, A. E. Kulikov, Z. Rasulov, M. Fedyanin, A. Polynovskiy","doi":"10.17650/2782-3202-2022-2-2-29-37","DOIUrl":"https://doi.org/10.17650/2782-3202-2022-2-2-29-37","url":null,"abstract":"Objective: To assess the impact of mesorectal excision for upper rectal cancer on long-term treatment results.Materials and methods. 227 patients with upper rectal cancer in the period between January 2004 and December 2014 were analyzed. The study included patients over 18 years of age with upper rectal cancer, stage T2-4N0-2M0. The patients were divided into 2 groups: partial mesorectal excision (PME) and total mesorectal excision (TME).Results. 226 (99.6 %) of 227 patients underwent surgical treatment. PME was performed in 199 (85.4 %) patients, TME in 27 (14.6 %) patients. TME was significantly more often performed in patients with preoperative treatment (р = 0.03). Operative time did not differ significantly between the two groups (TME - 186 minutes and PME - 168 minutes; р = 0.34). Postoperative complications were observed in 12.3 % of cases with no significant differences between the groups (TME - 14.3 %, PME - 12.1 %; р = 0.68). Anastomotic failure was noted in 7.1 % of cases, all in the PME group. Median follow-up was 57 months. The number of deaths was 29 (12.8 %), in the PME group - 27 (13.6 %), and in the TME group - 2 (7.4 %) (р = 0.61). Local recurrences developed in 4 (2.2 %) patients of the PME group and none in TME group. Distant metastases were diagnosed in 2 patients (8 %) of the TME group and 23 patients (12.1 %) of the PME group (р = 0.509). Overall 5-year survival in the TME group was 79.6 %, in the PME group - 86.3 % (р = 0.463), and 5-year disease-free survival was 79.3 % and 86 %, respectively (р = 0.521).Conclusion. Multivariate analysis showed that the volume of mesorectal excision did not affect the rate of disease recurrence and disease-free survival in both groups.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133044066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safe drug therapy in clinical practice: experience of using microinfusion single-use mechanical systems in treatment of patients with malignant diseases of hematopoietic tissue and solid tumors 临床安全药物治疗:应用微输注一次性机械系统治疗造血组织及实体肿瘤恶性疾病的体会

MD-Onco Pub Date : 2022-06-02 DOI: 10.17650/2782-3202-2022-2-2-51-62

Yu. E. Ryabukhina, P. A. Zeynalova, V. E. Gruzdev, M. A. Anisimov, A. Fedenko, O. L. Timofeeva, F. М. Abbasbeyli, D. A. Chekin, A. G. Zhukov

{"title":"Safe drug therapy in clinical practice: experience of using microinfusion single-use mechanical systems in treatment of patients with malignant diseases of hematopoietic tissue and solid tumors","authors":"Yu. E. Ryabukhina, P. A. Zeynalova, V. E. Gruzdev, M. A. Anisimov, A. Fedenko, O. L. Timofeeva, F. М. Abbasbeyli, D. A. Chekin, A. G. Zhukov","doi":"10.17650/2782-3202-2022-2-2-51-62","DOIUrl":"https://doi.org/10.17650/2782-3202-2022-2-2-51-62","url":null,"abstract":"Recently due to significant successes in drug therapy of malignant tumors, the question of quality of life of patients has become more important. Cyclical drug treatment implies intravenous infusion of antitumor agents. Complications associated with this type of therapy include phlebitis and extravasation and, in some cases, lead to full obliteration of vessel lumen and vast skin and hypoderm necrosis. Multiple venous punctions can with time lead to significant technical difficulties in accessing the vein and limit the continuation of therapy. This drives the necessity to search for rational approaches to patient safety during both outpatient and inpatient antitumor drug treatment. To solve this problem, fully implanted venous port systems were developed and implemented in clinical practice which provide organization of aseptic continuous venous access, as well as infusion pumps (for independent prolonged intravenous therapy). Use of these devices allows for continuity and cycling of treatment process, significantly improves patients' quality of life by not limiting daily activities.In the article we present our experience of using microinfusion single-use mechanical systems for antitumor drug therapy and relief of intense pain syndrome in patients with malignant disorders of hematopoietic tissue and solid tumors.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116990496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective application of integrative approach in treatment of neuroendocrine colon cancer. Clinical case 综合方法在神经内分泌结肠癌治疗中的有效应用。临床病例

MD-Onco Pub Date : 2022-03-04 DOI: 10.17650/2782-3202-2022-2-1-28-32

M. Davydov, P. A. Zeynalovа, A. Fedenko, E. K. Ibragimov, D. A. Chekiny, A. A. Filimonov, E. V. Dementievа

引用次数: 0

Does the level of medical facility impact short-term results of surgical treatment of colorectal cancer 医疗设施水平是否影响结直肠癌手术治疗的短期效果

MD-Onco Pub Date : 2022-03-04 DOI: 10.17650/2782-3202-2022-2-1-39-47

A. Rasulov, Z. Rasulov, J. Madyarov, A. E. Kulikov, Y. Stoyko, A. Maksimenkov, A. Botov, Sh. A. Alishikhov, Yu. E. Lʼvova, A. Otabekov

{"title":"Does the level of medical facility impact short-term results of surgical treatment of colorectal cancer","authors":"A. Rasulov, Z. Rasulov, J. Madyarov, A. E. Kulikov, Y. Stoyko, A. Maksimenkov, A. Botov, Sh. A. Alishikhov, Yu. E. Lʼvova, A. Otabekov","doi":"10.17650/2782-3202-2022-2-1-39-47","DOIUrl":"https://doi.org/10.17650/2782-3202-2022-2-1-39-47","url":null,"abstract":"The study objective was to evaluate the impact of medical hospital volume on short-term colorectal cancer treatment results.Materials and methods. The retrospective study included 93 patients with colorectal cancer operated on by one surgeon at two medical centers in Moscow from 2018 to 2020: 32 patients of the first group were operated in tertiary medical center (N.I. Pirogov National Medical and Surgical Center) and 61 of the second group – in regional low volume hospital (Centrosoyuz Hospital). The endpoints of the study were the short-term outcomes: surgery duration, blood loss, postoperative hospital stay, intra- and postoperative complications, lymph node harvested and the quality of specimen.Results. Surgery duration as well as blood loss in two groups were similar (258 min vs 240 min, p = 0.47 and 100 ml and 100 ml, p = 0.89, accordingly). Hospital stay after surgery was significantly less in the first group (9 days vs 16 days, p <0.01). The frequency of postoperative complications of type I–II according to the Clavien–Dindo classification was higher in the first group (6/8 vs 1/8, p <0.05) but reoperations performed more in the second group due to III Clavien–Dindo complications (2/8 vs 7/8, p = 0.012). Grade 2–3 rectal cancer specimen quality was 94.7 % vs 77.8 %, p = 0.13 and harvested lymph nodes >12 was 71.9 % vs 78.7 %, p = 0.485 in first and second group, respectively.Conclusion. Hospital volume does not affect rectal cancer specimen quality, surgery duration and blood loss, if the surgical interventions are performed by one experienced surgeon but associated with the incidence of postoperative complications and the length of stay.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134220749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical observation of cervical esophageal cancer 宫颈食管癌的临床观察

MD-Onco Pub Date : 2022-03-04 DOI: 10.17650/2782-3202-2022-2-1-19-27

A. Mudunov, A. Batsev, A. Maryenko, M. Shogenov

引用次数: 0

MD-Onco最新文献